Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01182077 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Drug Interaction of ASP015K and Midazolam
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01182077 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 30 participants.
The verdict
NCT01182077, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The objective of the study is to characterize the effect of multiple doses of ASP015K on the pharmacokinetics of a single dose of midazolam.
Interventions
- DRUG Midazolam
- DRUG ASP015K
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01182077
The ClinicalTrials.gov registry entry for NCT01182077 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midazolam is the first listed.
NCT01182077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01182077 about?
NCT01182077 is a clinical study titled "A Study to Assess Drug Interaction of ASP015K and Midazolam". The objective of the study is to characterize the effect of multiple doses of ASP015K on the pharmacokinetics of a single dose of midazolam.
What is the current status of trial NCT01182077?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-06. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01182077?
The interventions under investigation include: Midazolam (DRUG), ASP015K (DRUG).
Who is sponsoring clinical trial NCT01182077?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.